Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer

被引：0
|
作者：
Takayuki Iwamoto
Naoki Niikura
Kenichi Watanabe
Takashi Takeshita
Yuichiro Kikawa
Kokoro Kobayashi
Nobutaka Iwakuma
Takuho Okamura
Hiroshi Tada
Shinji Ozaki
Toshitaka Okuno
Uhi Toh
Yutaka Yamamoto
Michiko Tsuneizumi
Hiroshi Ishiguro
Norikazu Masuda
Shigehira Saji
机构：
[1] Kawasaki Medical School Hospital,Breast and Thyroid Surgery
[2] Okayama University Hospital,Breast and Endocrine Surgery
[3] Tokai University School of Medicine,Department of Breast Oncology
[4] Hokkaido Cancer Center,Breast Surgery
[5] Kumamoto City Hospital,Breast and Endocrine Surgery
[6] Kansai Medical University Hospital,Department of Breast Surgery
[7] Saitama Red Cross Hospital,Department of Medical Oncology
[8] Kyushu Medical Center,Breast Center, Department of Breast Surgery
[9] Tohoku University Hospital,Department of Surgery, Division of Breast and Endocrine Surgery
[10] Hiroshima Prefectural Hospital,Department of Gastrointestinal and Breast Surgery
[11] Kobe City Nishi-Kobe Medical Center,Department of Breast Surgery
[12] Kurume University Hospital,Department of Breast Surgery
[13] Kumamoto University Hospital,Department of Breast and Endocrine Surgery
[14] Shizuoka General Hospital,Department of Breast Surgery
[15] Saitama Medical University International Medical Center,Breast Oncology Service
[16] Nagoya University Graduate School of Medicine,Department of Breast and Endocrine Surgery
[17] Fukushima Medical University School of Medicine,Department of Medical Oncology
来源：
Breast Cancer Research and Treatment | 2024年 / 203卷
关键词：
Advanced breast cancer; Palbociclib; Fulvestrant; Cell-free DNA; Window of opportunity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：225 / 234
页数：9
相关论文
共 50 条
  • [31] Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update
    Burstein, Harold J.
    Somerfield, Mark R.
    Barton, Debra L.
    Dorris, Ali
    Fallowfield, Lesley J.
    Jain, Dharamvir
    Johnston, Stephen R. D.
    Korde, Larissa A.
    Litton, Jennifer K.
    Macrae, Erin R.
    Peterson, Lindsay L.
    Vikas, Praveen
    Yung, Rachel L.
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) : 3959 - +
  • [32] Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study
    Waller, John
    Mitra, Debanjali
    Mycock, Katie
    Taylor-Stokes, Gavin
    Milligan, Gary
    Zhan, Lin
    Iyer, Shrividya
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5
  • [33] Model Development of CDK4/6 Predicted Efficacy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
    Mason, Jeremy
    Gong, Yutao
    Amiri-Kordestani, Laleh
    Wedam, Suparna
    Gao, Jennifer J.
    Prowell, Tatiana M.
    Singh, Harpreet
    Amatya, Anup
    Tang, Shenghui
    Pazdur, Richard
    Kuhn, Peter
    Blumenthal, Gideon M.
    Beaver, Julia A.
    JCO CLINICAL CANCER INFORMATICS, 2021, 5 : 758 - 767
  • [34] A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy
    Xu, Fei
    Zheng, Qiufan
    Xia, Wen
    Ouyang, Quchang
    Pang, Danmei
    Yuan, Zhongyu
    Shi, Yanxia
    Peng, Roujun
    Lu, Qianyi
    Wang, Shusen
    ONCOLOGIST, 2021, 26 (05) : E742 - E748
  • [35] Palbociclib as an early-line treatment for Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: a review of clinical trial and real-world data
    Masuda, Norikazu
    Kosaka, Nobuyoshi
    Iwata, Hiroji
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2179 - 2193
  • [36] Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review
    Chu, Zhaohui
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] Comparison of Endocrine Therapies in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer: A Network Meta-Analysis
    Liu, Siqi
    Sun, Xin
    Xu, Xiaohui
    Lin, Fangcai
    JOURNAL OF BREAST CANCER, 2020, 23 (05) : 460 - 483
  • [38] Biomarkers for Cyclin-Dependent Kinase 4/6 Inhibitors in the Treatment of Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced/Metastatic Breast Cancer: Translation to Clinical Practice
    Bui, Tam Binh V.
    Burgering, Boudewijn M. T.
    Goga, Andrei
    Rugo, Hope S.
    van't Veer, Laura J.
    JCO PRECISION ONCOLOGY, 2022, 6 (01)
  • [39] Analysis of subsequent therapy in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and-3
    Masuda, Norikazu
    Mukai, Hirofumi
    Inoue, Kenichi
    Rai, Yoshiaki
    Ohno, Shinji
    Ohtani, Shoichiro
    Shimizu, Chikako
    Hashigaki, Satoshi
    Muramatsu, Yasuaki
    Umeyama, Yoshiko
    Iwata, Hiroji
    Toi, Masakazu
    BREAST CANCER, 2021, 28 (02) : 335 - 345
  • [40] Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
    Shen, Le-Sang
    Jin, Xiao-Yan
    Wang, Xu-Meng
    Tou, Lai-Zhen
    Huang, Jian
    CHINESE MEDICAL JOURNAL, 2020, 133 (09) : 1099 - 1108
12345